Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy

Cancer Gene Therapy

Volumn 13, Issue 4, 2006, Pages 346-356

  Liu, Y ^a   Ye, T ^a   Maynard, J ^a   Akbulut, H ^a   Deisseroth, A ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Breast cancer; CRAD; Cytosine deaminase; L plastin promoter; Transductional targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOSINE DEAMINASE; FLUCYTOSINE; GLYCOPROTEIN E1; PRODRUG; VIRUS RECEPTOR;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER THERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBRYO; GENE CONSTRUCT; GENE EXPRESSION; GENE INSERTION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICULATE MATTER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; VIRAL GENE THERAPY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; XENOTRANSPLANTATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICROFILAMENT PROTEINS; OLIGOPEPTIDES; PHOSPHOPROTEINS; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RECEPTORS, VITRONECTIN; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS;

EID: 33645020031     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700906     Document Type: Article

References (29)

1. Zhang W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999; 6: 113-138.
2. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
3. Wickham TJ. Targeting adenovirus. Gene Therapy 2000; 7: 110-114.
4. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expression the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
5. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
6. Kashentseva EA, Seki T, Curiel DT, Dmitriev IP. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2002; 62: 609-616.
7. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
8. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 1998; 58: 2588-2593.
9. Oliver W, Michael B, Jogn CM. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kniase. Cancer Res 1999; 59: 410-413.
10. Wildner O, Morris JC, Vahanian NN, Ford Jr H, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Therapy 1999; 6: 57-62.
11. Liang Y, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000; 60: 1009-1013.
12. Barker SD, Dmitriev IP, Nettelbeck DM, Liu B, Rivera AA, Alvarez RD et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy 2003; 10: 1198-1204.
13. Barnett BG, Tillman BW, Curiel DT, Douglas JT. Dual targeting of adenoviral vectors at the level of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther 2002; 6: 377-385.
14. Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balysnilova IV et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Bio 2001; 19: 838-842.
15. Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cell. Cancer Gene Ther 1999; 6: 99-106.
16. Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G et al. The use of L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res 2001; 61: 4405-4413.
17. Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of breast, ovary and colon. Cancer Gene Ther 2003; 10: 388-395.
18. Liu YZ, Ye T, Sun DJ, Maynard J, Deisseroth A. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in the gene therapy of melanoma. Human Gene Ther 2004; 15: 637-647.
19. He TC, Zhou SB, Costal LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
20. 5 promoter adenovirus internalization but not virus attachment. Cell 1994; 73: 309-319.
21. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Human Gene Ther 1999; 10: 1721-1733.
22. Lin CS, Chang CH, Huynh T. The murine L-plastin gene promoter: identification and comparison with the human L-plastin gene promoter. DNA Cell Biol 1997; 1: 9-16.
23. Zhang L, Akbulut H, Tang Y, Peng X, Pizzorno G, Sapi E et al. Adenovirus vectors with E1A Regulated by Tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Mol Ther 2002; 6: 386-393.
24. Louis N, Fender P, Barge A, Kitts P, Chroboczek J. Cell-binding domain of adenovirus serotype 2 fiber. J Virol 1994; 68: 4104-4106.
25. Xia D, Henry LJ, Gerard RD, Gerard RD, Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus 5 fiber protein at 1.7A resolution. Structure 1994; 2: 1259-1270.
26. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9731.
27. Roelvink PW, Mi LG, Einfeld DA, Kovesdi Z, Wickham TJ. Identification of a conserved receptor-binding site on the fiber protein of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
28. Jakubczak JL, Rollence ML, Stewart DA, Jafari JD, Von Seggern DJ, Nemerow GR et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber protein show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol 2001; 75: 2972-2981.
29. Okegawa T, Pong RC, Li YM, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of CAR protein structure. Cancer Res 2001; 61: 6592-6600.